Investment in R&D is at the core of our business and we make sure we carry out our research to high ethical and quality standards in all the countries in which we operate. Whether it’s a patient’s safety during a clinical trial or the necessary use of an animal in our research, we always apply recognised standards and principles of good medical science, integrity and ethics.
We aim to address any concerns by being open about our research and regularly engaging with academic scientists, regulators, policymakers and other stakeholders.
Transparency of our research
We are committed to reporting the results of clinical research into our medicines and vaccines, whether the outcomes are positive or negative. We do this by:
- posting the results of our research on our publicly accessible Clinical Study Register website
- seeking to publish all research results as full papers in peer-reviewed scientific journals
- enabling researchers to access detailed anonymised patient-level data from trials
- expanding the information made publically available on our Clinical Study Register
The Clinical Study Register - which receives on average over 12,600 visits each month - now includes more than 5,500 summaries of trial results, which are posted regardless of whether the outcomes might be considered positive or negative. In 2013, we expanded this to include Clinical Study Reports (CSRs) – formal study reports on the design, methods and results of clinical trials which form the basis of submissions to regulatory agencies. In May 2013, we became the first company to launch an online system to provide researchers with access to the underlying data to conduct further research. In January 2014, we launched www.clinicalstudydatarequest.com to include data from other companies. By the end of 2014, GSK and nine other companies had used this system. We are encouraging the development of an independent system that will include studies from across the industry and academia.
Sharing our research
In addition, we are being more open with our expertise and know-how and around research into neglected tropical diseases, and looking to share our intellectual property where appropriate to further innovation targeting diseases.